BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 1.06B |
| Revenue (ttm) | 70.95M |
| Net Income (ttm) | -595.86M |
| Shares Out | 147.69M |
| EPS (ttm) | -3.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 633,038 |
| Open | 7.14 |
| Previous Close | 7.43 |
| Day's Range | 7.03 - 7.40 |
| 52-Week Range | 4.98 - 65.33 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 26.07 (+262.8%) |
| Earnings Date | May 5, 2022 |
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 cli...
Financial Performance
In 2021, BBIO's revenue was $69.72 million, an increase of 745.14% compared to the previous year's $8.25 million. Losses were -$562.54 million, 25.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 26.07, which is an increase of 262.84% from the latest price.
News
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment o...
- Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Pot...
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and can...
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
BridgeBio Pharma Inc (NASDAQ: BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and exit...
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
–Completed sale to Sentynl Therapeutics of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib i...
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyl...
- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBN...
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Am...
PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and c...
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and w...
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address bo...
BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and c...
BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY™ (Fosdenop...
PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases an...
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio's financial runway into 2024
Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such inves...
BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know
BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital ...
- If successful, BridgeBio's investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body's hormone and steroid balance by enabling people with CAH to make their own corti...
BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, i...
- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation
BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas...